Table 1 Compiled eligible studies included in the meta-analysis of rk39 in Ethiopia
Author | Year | TP | FN | FP | TN | Ref. test | Sample type | Control group | Sens (95% CI) | Spec (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|
Asrat et al. HIV- (DiaMed) | 2014 | 80 | 2 | 2 | 109 | DAT | Serum | Healthy non-endemic, Healthy endemic & Other disease control | 0.976 (0.98–0.99) | 0.982 (0.93–0.99) |
Asrat et al. HIV- (InBios) | 2014 | 77 | 5 | 2 | 109 | DAT | Serum | Healthy non-endemic, Healthy endemic & Other disease control | 0.939 (0.88–0.97) | 0.982 (0.98–0.93) |
Asrat et al. HIV + (DiaMed) | 2014 | 12 | 1 | 0 | 0 | DAT | Serum | Healthy non-endemic, Healthy endemic & Other disease control | 0.893 (0.60–0.98) | 0.500 (0.02–0.98) |
Asrat et al. HIV + (InBios) | 2014 | 11 | 2 | 0 | 0 | DAT | Serum | Healthy non-endemic & Healthy endemic & Other disease control | 0.821 (0.54–0.95) | 0.500 (0.02–0.98) |
Boelaert et al. (InBios) | 2008 | 15 | 5 | 5 | 10 | DAT | Serum | Endemic patient control | 0.750 (0.52–0.89) | 0.667 (0.41–0.85) |
Carmen et al. (DiaMed) | 2011 | 32 | 3 | 4 | 63 | Microscopy | Serum | Healthy endemic control | 0.914 (0.77–0.97) | 0.940 (0.85–0.98) |
Carmen et al. (InBios) | 2011 | 33 | 2 | 1 | 66 | Microscopy | Serum | Health endemic control | 0.943 (0.80–0.99) | 0.985 (0.90–0.99) |
Diro et al. (DiaMed) | 2015 | 165 | 22 | 72 | 104 | Microscopy&NNN | Serum | Endemic patient control | 0.882 (0.83–0.92) | 0.591 (0.52–0.66) |
Diro et al. (InBios) | 2007 | 35 | 14 | 9 | 43 | Microscopy&NNN | Serum | Endemic patient control | 0.714 (0.57–0.82) | 0.827 (0.70–0.91) |
Kiros et al.(InBios) | 2017 | 37 | 7 | 13 | 5 | Microscopy | Serum | Endemic patient control | 0.841 (0.70–0.92) | 0.278 (0.12–0.52) |
ter Horst et al. HIV + (DiaMed) | 2009 | 136 | 32 | 2 | 9 | Micoscopy | Dried blood spot(DBS) | Other diseased patients | 0.810 (0.74–0.86) | 0.818 (0.49–0.95) |
ter Horst et al. HIV- (DiaMed) | 2009 | 42 | 23 | 2 | 4 | Microscopy | DBS | Other diseased patients | 0.646 (0.52–0.75) | 0.667 (0.27–0.92) |
Sarfaraz et al. (InBios) | 2019 | 85 | 1 | 0 | 0 | Microscopy | Serum | Other diseased patient & healthy endemic | 0.983 (0.92–0.99) | 0.500 (0.02–0.98) |
Getachew et al. (DiaMed) | 2019 | 11 | 0 | 46 | 304 | *ELISA | Whole blood | Endemic Patient control | 0.958 (0.58–0.99) | 0.868 (0.82–0.90) |
Endalamaw et al. (InBios) | 2012 | 2 | 6 | 0 | 23 | DAT | DBS | Endemic patient control | 0.278 (0.08–0.62) | 0.979 (0.74–0.99) |
Canavate et al. (Diamed) | 2011 | 223 | 23 | 0 | 0 | PCR | Serum | Healthy endemic | 0.905 (0.86–0.94) | 0.500 (0.02–0.98) |
Canavate et al. (Inbios) | 2011 | 219 | 27 | 0 | 0 | PCR | Serum | Healthy endemic | 0.889 (0.84–0.92) | 0.500 (0.02–0.98) |
Alelign et al. (InBios) | 2020 | 106 | 4 | 11 | 75 | Micoscopy | Serum | Other diseased patient & healthy control | 0.96 (0.91–0.99) | 0.87 (0.78–0.93) |